March 19, 2019 / 9:45 PM / a year ago

CORRECTED-Sage gets U.S. approval for first postpartum depression therapy

(Corrects paragraphs 1 and 2 to remove reference to "severe")

March 19 (Reuters) - The U.S. Food and Drug Administration on Tuesday approved here Sage Therapeutics Inc's drug for postpartum depression, marking the first approval of a treatment specifically developed for the condition that affects a new mother's ability to care for herself or her baby.

The drug, which is administered to new mothers as a single 60-hour intravenous infusion, is chemically identical to the hormone allopregnanolone.

The company said it will price the treatment, to be sold under the brand name Zulresso, at between $20,000 to $35,000, and that it expects broad reimbursement based on feedback from insurers. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Bill Berkrot)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below